Telix doses first patient in Phase 3 kidney cancer drug trial

July 20, 2026 5:00 PM

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) announced that the first patient has been dosed in the LUTEON Phase 3 clinical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found